Polypeptide specific for mucin 1 and use thereof

An antibody or an antigen-binding fragment thereof binding to mucin1, the antibody or antigen-binding fragment thereof comprising a pair of a heavy chain variable (VH) region and a light chain variable (VL) region selected from the following VH and VL regions:

• a VH region comprising complementarity-determining region (CDR) 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 1, SEQ ID NO:
• 2, and SEQ ID NO:
• 3, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 4, SEQ ID NO:
• 5, and SEQ ID NO:
• 6, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 11, SEQ ID NO:
• 12, and SEQ ID NO:
• 13, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 14, SEQ ID NO:
• 15, and SEQ ID NO:
• 16, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 21, SEQ ID NO:
• 22, and SEQ ID NO:
• 23, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 24, SEQ ID NO:
• 25, and SEQ ID NO:
• 26, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 31, SEQ ID NO:
• 32, and SEQ ID NO:
• 33, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 34, SEQ ID NO:
• 35, and SEQ ID NO:
• 36, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 41, SEQ ID NO:
• 42, and SEQ ID NO:
• 43, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 44, SEQ ID NO:
• 45, and SEQ ID NO:
• 46, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 51, SEQ ID NO:
• 52, and SEQ ID NO:
• 53, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 54, SEQ ID NO:
• 55, and SEQ ID NO:
• 56, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 61, SEQ ID NO:
• 62, and SEQ ID NO:
• 63, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 64, SEQ ID NO:
• 65, and SEQ ID NO:
• 66, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 71, SEQ ID NO:
• 72, and SEQ ID NO:
• 73, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 74, SEQ ID NO:
• 75, and SEQ ID NO:
• 76, respectively;
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 81, SEQ ID NO:
• 82, and SEQ ID NO:
• 83, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 84, SEQ ID NO:
• 85, and SEQ ID NO:
• 86, respectively;
• or
• a VH region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 91, SEQ ID NO:
• 92, and SEQ ID NO:
• 93, respectively, and a VL region comprising CDR 1, CDR 2, and CDR 3 comprising amino acid sequences of SEQ ID NO:
• 94, SEQ ID NO:
• 95, and SEQ ID NO:
• 96, respectively.